Canopus plans to acquire 90% equity of Wuhan Yijiaobao, which is expected to constitute a major asset reorganization
I'm LongbridgeAI, I can summarize articles.Canopus plans to acquire 90% equity of Wuhan Yijiaobao in cash, which is expected to constitute a significant asset restructuring. Wuhan Yijiaobao focuses on the research, production, and sales of high-end orthopedic and biomedical materials. This transaction aims to integrate industry resources, extend the surgical medical device industry chain, actively expand into the synthetic biology field, and enhance the company's overall strength, which is expected to have a positive impact on future business development and operating performance
According to the Zhitong Finance APP, Dongxing Medical (301290.SZ) announced that the company intends to purchase 90% of the equity of Wuhan Yijiaobao Biological Materials Co., Ltd. (referred to as "Wuhan Yijiaobao") through cash payment. If this transaction is successfully implemented, Wuhan Yijiaobao will become a subsidiary controlled by the company. Based on preliminary research and calculations, this transaction is expected to constitute a major asset reorganization as defined by the "Administrative Measures for Major Asset Restructuring of Listed Companies."
Wuhan Yijiaobao is a high-tech enterprise dedicated to the research, production, and sales of high-end orthopedic and biomedical materials. This transaction is a prudent decision made based on the company's business development strategy and long-term interests, aligning with the company's goal of integrating high-quality industry resources, extending the surgical medical device industry chain, and actively expanding the development layout in the synthetic biology field. It is beneficial for enhancing the company's overall strength and will have a positive impact on the company's future business development and operational performance